It’s been little more than a month since we held the P4SY Showcase & MedTech Conference for the first cohort of P4SY companies in Sheffield, and so we are excited to make another major P4SY announcement: the full list of companies participating in Cohort 2.
These Cohort 2 companies were selected from more than 60 applicants through a rigorous assessment process led by the Capital Enterprise team. Over the next 6 months, each company will receive tailored support to help them scale-up and achieve their milestones – including connections to the regional health and care system and our investor networks.
We are very pleased to welcome the following companies to P4SY’s Cohort 2.
MedQ works with healthcare providers to transition from paper assessments to remote patient monitoring through a simple digital process. Patient-reported outcome measures (PROMs) are a key part of how GPs and clinics manage and evaluate their services and digitising these assessments is a major opportunity for savings and efficiencies.
Plasma4 is developing a technology based on cold atmospheric plasma (CAP) with medical and veterinary applications. The company’s novel, patent-protected platform provides a means to deliver filtered CAP and therapeutic agents deep into tissue. Skin is the initial target organ, where Plasma4 technology can, for example, accelerate wound healing and reduce infection risks.
Nanordica Medical has invented and patented nanotechnology that provides treatment for infected wounds that is eight times more effective than the standard of care. With a major clinical trial underway, this technology will soon be used to manufacture a wide range of antibacterial products like wound dressings, sprays, creams, and more.
Therapha is on a mission to accelerate the speed with which patients with self-reported symptoms can be triaged and diagnosed. Their musculoskeletal triaging tool combines evidence-based research and artificial intelligence (AI) to support clinical decision-making based on a self-reported history and symptoms.
A spinout from the University of Sheffield, MetalloBio is developing two novel ruthenium-based antimicrobial compounds that will be used to treat multidrug resistant pathogens. The company’s inorganic chemistry platform is capable of creating powerful antimicrobial agents for pharmaceutical drugs, medical devices, material coatings and additives – critical technology as antimicrobial resistance (AMR) becomes a growing threat to global health.
Hashiona is a femtech-focused digital platform for the management and treatment of Hashimoto’s disease, a leading cause of hypothyroidism, a chronic condition which disproportionately affects older women. Hashiona aims to become a vertically integrated healthcare provider for thyroid disorders, creating a digital therapeutic and a virtual clinic addressing the problem of the growing global shortage of endocrinologists.
SOAP Health has developed an AI-driven clinical decision-making support tool which aims to reduce clinical errors and misdiagnoses, reduce data entry burdens, and save clinician time by documenting up to 90% of a patient encounter. Last year, SOAP Health was selected by the highly competitive Mayo Clinic accelerator programme to further develop the AI models based on 3 million longitudinal patient records.
In collaboration with the University of Sheffield, EveryBaby aims to address the low accuracy of transvaginal ultrasounds at predicting preterm births. The company has developed a patented handheld medical device that provides a more accurate and easier-to-use alternative, and a clinical trial involving 449 pregnant women has already demonstrated the diagnostic accuracy of the EveryBaby probe.
Pentabind’s AI-driven platform targets and maps previously undruggable human proteins, drivers of multiple cancers and diseases. By applying a powerful approach to rapidly design Oligos (short, single-stranded RNA or DNA sequences), they leverage recent breakthroughs in mRNA vaccine development. These tools enable rapid and high-throughput screening of drug candidates and mapping of human proteins.
Cansor has developed a point-of-care test for prostate cancer with high sensitivity and specificity using cell-free DNA and state-of-the-art AI technology. Anjui Wu, the company’s co-founder and CEO, recently won Cancer Research Horizon’s top award for Early-Career Entrepreneurs at the 2022 Innovation and Entrepreneurship Awards.
Combining cognitive behavioural therapy (CBT) with virtual reality, XR Therapeutics is developing a treatment to support people with phobias and anxieties. The product of over 9 years of academic research and clinical trials, the company’s technology reduces waiting times and treats patients effectively within 2 weeks, as opposed to 12+ weeks for traditional CBT.
CNS Therapy is developing a new strategy to eliminate chronic pain by combining a new physiological approach (cardiac gated stimulation) with a psychological approach (digitally-delivered behavioural therapy guided by biometric data). This new technique is low risk, non-invasive, and, with the help of a patented device that enhances learning and resets the autonomic nervous system, has already proven to be highly successful.
Planet Nourish aims to improve health outcomes for underrepresented populations with an ethnically-focused Prevention as a Service (PaaS) digital platform delivering hyper-personalised food, lifestyle, and behavioural change recommendations. The company’s first product is a culturally tailored programme for the prevention of diet-related health conditions for South Asian communities, and has already been used by more than 1,500 beta testers.
Turbinia is building software that enables pharmaceutical companies to create more and better drugs by understanding the many impacts modified proteins have on biology. Turbina has a highly experienced team that knows the market and the customers, and biomarker discovery technology developed over the last 12 years.
Welcome to P4SY Cohort 2!